Stress-induced Pain: a Target for the Development of Novel Therapeutics

Overview

Journal J Pharmacol Exp Ther

Specialty Pharmacology

Date 2014 Sep 7

PMID 25194019

Citations 18

Authors

Anthony C Johnson

Beverley Greenwood-Van Meerveld

Affiliations

Soon will be listed here.

Abstract

Although current therapeutics provide relief from acute pain, drugs used for treatment of chronic pain are typically less efficacious and limited by adverse side effects, including tolerance, addiction, and gastrointestinal upset. Thus, there is a significant need for novel therapies for the treatment of chronic pain. In concert with chronic pain, persistent stress facilitates pain perception and sensitizes pain pathways, leading to a feed-forward cycle promoting chronic pain disorders. Stress exacerbation of chronic pain suggests that centrally acting drugs targeting the pain- and stress-responsive brain regions represent a valid target for the development of novel therapeutics. This review provides an overview of how stress modulates spinal and central pain pathways, identifies key neurotransmitters and receptors within these pathways, and highlights their potential as novel targets for therapeutics to treat chronic pain.

Citing Articles

Design, Synthesis, and Evaluation of a New Series of Indole-Chalcone Hybrids as Analgesic and Anti-Inflammatory Agents.

Baramaki I, Altintop M, Arslan R, Altinok F, Ozdemir A, Dallali I ACS Omega. 2024; 9(10):12175-12183.

PMID: 38497028 PMC: 10938421. DOI: 10.1021/acsomega.4c00026.

Reproducible microbiome composition signatures of anxiety and depressive symptoms.

Kouraki A, Kelly A, Vijay A, Gohir S, Astbury S, Georgopoulos V Comput Struct Biotechnol J. 2023; 21:5326-5336.

PMID: 37954149 PMC: 10637863. DOI: 10.1016/j.csbj.2023.10.035.

Peritraumatic Pain in Child Maltreatment: A Systematic Literature Review.

Tsur N, Talmon A, Shemesh N Trauma Violence Abuse. 2023; 25(3):1725-1736.

PMID: 37655587 PMC: 11155214. DOI: 10.1177/15248380231194069.

Resilience, pain, and the brain: Relationships differ by sociodemographics.

Tanner J, Johnson A, Terry E, Cardoso J, Garvan C, Staud R J Neurosci Res. 2021; 99(5):1207-1235.

PMID: 33606287 PMC: 8634062. DOI: 10.1002/jnr.24790.

Interrelations between pain, stress and executive functioning.

Feller L, Feller G, Ballyram T, Chandran R, Lemmer J, Khammissa R Br J Pain. 2020; 14(3):188-194.

PMID: 32922780 PMC: 7453485. DOI: 10.1177/2049463719889380.

References

Reichling D, Green P, Levine J . The fundamental unit of pain is the cell. Pain. 2013; 154 Suppl 1:S2-9. PMC: 3858489. DOI: 10.1016/j.pain.2013.05.037. View

Takasaki I, Kurihara T, Saegusa H, Zong S, Tanabe T . Effects of glucocorticoid receptor antagonists on allodynia and hyperalgesia in mouse model of neuropathic pain. Eur J Pharmacol. 2005; 524(1-3):80-3. DOI: 10.1016/j.ejphar.2005.09.045. View

Bouchard P, Quirion R . [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience. 1997; 76(2):467-77. DOI: 10.1016/s0306-4522(96)00221-7. View

Hammes S, Levin E . Minireview: Recent advances in extranuclear steroid receptor actions. Endocrinology. 2011; 152(12):4489-95. PMC: 3858720. DOI: 10.1210/en.2011-1470. View

Navratilova E, Xie J, King T, Porreca F . Evaluation of reward from pain relief. Ann N Y Acad Sci. 2013; 1282:1-11. PMC: 4028681. DOI: 10.1111/nyas.12095. View

Dong F, Xie W, Strong J, Zhang J . Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. Anesthesiology. 2012; 117(5):1102-12. PMC: 3482280. DOI: 10.1097/ALN.0b013e3182700383. View

Barnard E, Skolnick P, Olsen R, Mohler H, Sieghart W, Biggio G . International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. Pharmacol Rev. 1998; 50(2):291-313. View

Vaughn L, Mantsch J, Vranjkovic O, Stroh G, Lacourt M, Kreutter M . Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. Neuroscience. 2011; 204:117-24. PMC: 3422566. DOI: 10.1016/j.neuroscience.2011.08.021. View

Wang S, Lim G, Zeng Q, Sung B, Yang L, Mao J . Central glucocorticoid receptors modulate the expression and function of spinal NMDA receptors after peripheral nerve injury. J Neurosci. 2005; 25(2):488-95. PMC: 6725479. DOI: 10.1523/JNEUROSCI.4127-04.2005. View

10.

Maizels M, Aurora S, Heinricher M . Beyond neurovascular: migraine as a dysfunctional neurolimbic pain network. Headache. 2012; 52(10):1553-65. DOI: 10.1111/j.1526-4610.2012.02209.x. View

11.

Lampe A, Doering S, Rumpold G, Solder E, Krismer M, Kantner-Rumplmair W . Chronic pain syndromes and their relation to childhood abuse and stressful life events. J Psychosom Res. 2003; 54(4):361-7. DOI: 10.1016/s0022-3999(02)00399-9. View

12.

Palazzo E, Marabese I, de Novellis V, Rossi F, Maione S . Supraspinal metabotropic glutamate receptors: a target for pain relief and beyond. Eur J Neurosci. 2014; 39(3):444-54. DOI: 10.1111/ejn.12398. View

13.

Tao Y . AMPA receptor trafficking in inflammation-induced dorsal horn central sensitization. Neurosci Bull. 2012; 28(2):111-20. PMC: 3324122. DOI: 10.1007/s12264-012-1204-z. View

14.

Timmermans W, Xiong H, Hoogenraad C, Krugers H . Stress and excitatory synapses: from health to disease. Neuroscience. 2013; 248:626-36. DOI: 10.1016/j.neuroscience.2013.05.043. View

15.

Yarushkina N, Bagaeva T, Filaretova L . Analgesic actions of corticotropin-releasing factor (CRF) on somatic pain sensitivity: involvement of glucocorticoid and CRF-2 receptors. Neurosci Behav Physiol. 2009; 39(9):819-23. DOI: 10.1007/s11055-009-9212-9. View

16.

Harmar A, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna J . Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012; 166(1):4-17. PMC: 3415633. DOI: 10.1111/j.1476-5381.2012.01871.x. View

17.

Crock L, Kolber B, Morgan C, Sadler K, Vogt S, Bruchas M . Central amygdala metabotropic glutamate receptor 5 in the modulation of visceral pain. J Neurosci. 2012; 32(41):14217-26. PMC: 3494864. DOI: 10.1523/JNEUROSCI.1473-12.2012. View

18.

Missig G, Roman C, Vizzard M, Braas K, Hammack S, May V . Parabrachial nucleus (PBn) pituitary adenylate cyclase activating polypeptide (PACAP) signaling in the amygdala: implication for the sensory and behavioral effects of pain. Neuropharmacology. 2014; 86:38-48. PMC: 4322675. DOI: 10.1016/j.neuropharm.2014.06.022. View

19.

Kataoka K, Hara K, Haranishi Y, Terada T, Sata T . The antinociceptive effect of SNAP5114, a gamma-aminobutyric acid transporter-3 inhibitor, in rat experimental pain models. Anesth Analg. 2013; 116(5):1162-1169. DOI: 10.1213/ANE.0b013e318282dda7. View

20.

Jinzenji A, Sogawa C, Miyawaki T, Wen X, Yi D, Ohyama K . Antiallodynic action of 1-(3-(9H-Carbazol-9-yl)-1-propyl)-4-(2-methyoxyphenyl)-4-piperidinol (NNC05-2090), a betaine/GABA transporter inhibitor. J Pharmacol Sci. 2014; 125(2):217-26. DOI: 10.1254/jphs.13146fp. View